Monday, August 27, 2018

Treating chronic HBV with tenofovir disoproxil reduces HCC risk

Individuals who are treated with tenofovir disoproxil for chronic hepatitis B virus (HBV) infection have a decreased risk of developing hepatocellular carcinoma (HCC), according to a recent study.

No comments:

Post a Comment